- Home
- AKA vs SERA Comparison
AKA vs SERA Comparison
Compare AKA & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- SERA
- Stock Information
- Founded
- AKA 2018
- SERA 2008
- Country
- AKA United States
- SERA United States
- Employees
- AKA N/A
- SERA N/A
- Industry
- AKA Catalog/Specialty Distribution
- SERA Precision Instruments
- Sector
- AKA Consumer Discretionary
- SERA Health Care
- Exchange
- AKA Nasdaq
- SERA Nasdaq
- Market Cap
- AKA 251.5M
- SERA 208.7M
- IPO Year
- AKA 2021
- SERA 2021
- Fundamental
- Price
- AKA $20.00
- SERA $8.35
- Analyst Decision
- AKA Buy
- SERA
- Analyst Count
- AKA 4
- SERA 0
- Target Price
- AKA $26.25
- SERA N/A
- AVG Volume (30 Days)
- AKA 7.5K
- SERA 87.5K
- Earning Date
- AKA 11-07-2024
- SERA 11-06-2024
- Dividend Yield
- AKA N/A
- SERA N/A
- EPS Growth
- AKA N/A
- SERA N/A
- EPS
- AKA N/A
- SERA N/A
- Revenue
- AKA $564,586,000.00
- SERA $94,000.00
- Revenue This Year
- AKA $5.44
- SERA N/A
- Revenue Next Year
- AKA $4.25
- SERA $4,471.43
- P/E Ratio
- AKA N/A
- SERA N/A
- Revenue Growth
- AKA 3.31
- SERA N/A
- 52 Week Low
- AKA $7.00
- SERA $4.90
- 52 Week High
- AKA $33.73
- SERA $12.36
- Technical
- Relative Strength Index (RSI)
- AKA 41.90
- SERA 57.84
- Support Level
- AKA $19.42
- SERA $7.91
- Resistance Level
- AKA $21.90
- SERA $8.60
- Average True Range (ATR)
- AKA 1.43
- SERA 0.58
- MACD
- AKA -0.01
- SERA 0.07
- Stochastic Oscillator
- AKA 19.78
- SERA 67.96
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.